TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Down 45.5% in November

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) was the recipient of a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 31,800 shares, a drop of 45.5% from the October 31st total of 58,400 shares. Approximately 0.7% of the company’s shares are sold short. Based on an average trading volume of 44,200 shares, the short-interest ratio is presently 0.7 days.

TriSalus Life Sciences Stock Performance

TLSI traded up $0.31 during mid-day trading on Friday, reaching $4.56. 12,179 shares of the stock were exchanged, compared to its average volume of 39,311. TriSalus Life Sciences has a 1 year low of $3.61 and a 1 year high of $10.42. The stock has a market capitalization of $139.05 million, a PE ratio of -1.83 and a beta of 0.49. The company has a 50 day moving average price of $4.23 and a two-hundred day moving average price of $5.43.

Analyst Upgrades and Downgrades

TLSI has been the subject of a number of research reports. Oppenheimer assumed coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They issued an “outperform” rating and a $10.00 price target for the company. Canaccord Genuity Group cut their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Northland Securities started coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective on the stock. Finally, Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, TriSalus Life Sciences currently has a consensus rating of “Buy” and a consensus target price of $12.08.

Insiders Place Their Bets

In other TriSalus Life Sciences news, CEO Mary T. Szela purchased 7,520 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were purchased at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the acquisition, the chief executive officer now owns 377,382 shares of the company’s stock, valued at approximately $1,962,386.40. This represents a 2.03 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders acquired 19,560 shares of company stock worth $95,190. Company insiders own 32.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLSI. Walleye Capital LLC purchased a new stake in TriSalus Life Sciences in the 3rd quarter valued at about $66,000. Virtu Financial LLC bought a new position in shares of TriSalus Life Sciences in the third quarter valued at approximately $92,000. Vestcor Inc purchased a new stake in shares of TriSalus Life Sciences during the third quarter valued at approximately $108,000. MSD Partners L.P. bought a new stake in TriSalus Life Sciences during the third quarter worth $184,000. Finally, Wolverine Asset Management LLC purchased a new position in TriSalus Life Sciences in the second quarter worth $240,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.